Therapeutics Company Announces Promising Results From Pilot Program
Vivos Therapeutics Reveals Encouraging Outcomes from a 7-Month, Multi-Site Pilot Study of Its Innovative Provider-Based Marketing and Distribution Approach.
On June 12, 2024, Vivos Therapeutics, Inc. (“Vivos” or the “Company”) announced promising results from a seven-month pilot program testing a new provider-based marketing and distribution model. Vivos Therapeutics specializes in developing and commercializing treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults. The pilot program's outcomes offer valuable insights into the efficacy and potential impact of this novel approach. $Vivos Therapeutics(VVOS.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
